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MANDATORY TESTING OF PREGNANT
WOMEN AND NEWBORNS: HIV, DRUG USE,

AND WELFARE POLICY
Wendy Chavkin*
Deborah Elman**
Paul H. Wise***
Fallout from the abortion debate includes changes in the public
conversation about pregnant women. An emerging strand of
thought depicts them as so self centered that their selfish indifference, even hostility to the fetus, must be constrained by outside
intervention. Thus, in the 1980s, debate focused on the legality of
imposing medical interventions, such as blood transfusions or
cesarean sections, on competent, dissenting pregnant women.' Towards the latter part of the decade, the focus shifted away from
these cases and concentrated on women with stigmatized conditions, such as drug addiction and HIV infection. Such deviant status was construed to be willful hostility towards the fetus. The
majority of imposed interventions involved identification through
testing, and reporting the women to state authorities. Child protective and criminal justice sanctions sometimes followed such
identification. 2
I. Substance Abuse
The author's research team conducted surveys in 1992 and 1995
of all of the State Directors of Substance Abuse, HIV and Child
Protective Services regarding policies and programs for affected
mothers.' Our first survey revealed a tension between interdiction
* Please address all correspondence to: Wendy Chavkin, MD, MPH, Associate
Professor of Clinical Public Health, Columbia University, Center for Population and
Family Health, 60 Haven Ave., B3, New York, NY 10032, phone:(212) 304-5220,
fax:(212) 305-7024.
** MPH, MIA, Columbia University, Center for Population and Family Health.
*** MD, MPH, Associate Professor of Pediatrics, Boston University School of
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1. V.E.B. Kolder et al., Court-OrderedObstetricalInterventions, 316 NEW ENG. J.
MED. 1192, 1192-96 (1987).
2. Wendy Chavkin et al., Finding Common Ground: Necessity of an Integrated
Agenda for Women's and Children's Health, 22 J.L. MED. & ETHICs 262, 266-67
(1994).
3. Wendy Chavkin et al., Efforts to Reduce PerinatalMortality, HIV, and Drug
Addiction: Survey of the States, 50 JAMA 164, 165 (1995); Wendy Chavkin et al.,
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and treatment efforts as well as a lack of coordination with other
public health initiatives directed at reproductive and infant health.4
The first survey came after efforts to improve services for women
had begun. Such efforts included the 1988 Congressional mandate
requiring that states (1) increase the portion of the budget "setaside" for the treatment of pregnant women and women with children, from 5% to 10%, (2) give pregnant women priority enrollment in treatment, as well as specific services such as prenatal care
and child care, and (3) establish demonstration programs for drugusing women.5 These efforts reflected a public health approach to
the problem, and promised improved access and availability of substance-abuse treatment for addicted pregnant women and mothers.
This hope was followed, however, by the Congressional elections of
1994, the ensuing budget cuts, the devolution of budgetary and regulatory authority to the states, and the shift to Medicaid managed
care.
In 1995, our second survey demonstrated a conflicting trend in
funding and oversight. Federal funding for substance abuse services which had initially increased, (largely through block grants), in
eighteen of the states, was in the process of being replaced by local
control of services and reduced local funding.' At the same time,
respondents from thirty-four states reported that cases of criminal
prosecution had transpired in their states, a significant increase
from the twenty-two states that had reported such cases in 1992. 7
Moreover, reporting of positive newborn urine toxicology results
had increased significantly; about two thirds of states report such
cases to Child Protective authorities, and ten states mandated that
positive newborn toxicology results be reported to the Criminal
Justice system (significantly more than the three which did so in
1992).8 Approximately a quarter of the states reported that pregnant drug users and mothers were mandated to treatment. 9
National Survey of the States: Policies and Practices Regarding Drug-Using Pregnant
Women, AM. J. PUB. HEALTH (in press for 1998) (on file with author) [hereinafter
National Survey].
4. See National Survey, supra note 3.
5. UNITED STATES GENERAL ACCOUNTING OFFICE, ADMS BLOCK GRANT:
DRUG TREATMENT SERVICES COULD BE IMPROVED By NEW ACCOUNTABILITY PROGRAM, REPORT TO THE CHAIRMAN OF THE HOUSE SELECT COMMITrEE ON NARCOTICS ABUSE AND CONTROL (1991) [hereinafter GAO REPORT].

6.
7.
8.
9.

Id., n.3.
Id.
Id.
Id.
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A similar pattern of increased governmental intervention and
decreased resources prevails in New York City. Mayor Rudolph
Giuliani closed the fifteen treatment programs established by the
previous administration for drug using mothers, called for widespread testing, and for presumptive removals of newborns with
positive toxicology results. 10 The following is a table of our rough
estimate of the costs involved in universal testing (based on tests
alone, not counting costs of personnel and other operational
expenses).
Estimates of New York State and New York City
Universal Toxicology Testing Costs 1
TEST

Screen 12

Urine Drug
Urine Drug and
Alcohol Screens
Meconium Drug Screen
Blood Alcohol Screen
Urine, Blood and
Meconium Alcohol/
Drug Screens

NEW YORK STATE

NEW YORK CITY

$26.1 million

$12 million

$47.1 million
$26.6 million
$22.2 million

$21.6 million
$12.2 million
$10.2 million

$95.9 million

$44 million

Interestingly, according to birth certificate data, the prevalence
of maternal drug use actually declined during this period, by about
20% from 1994-95.13
II.

HIV

In 1987 the Centers for Disease Control and Prevention (CDC)
began the National HIV Survey of Childbearing Women, to track
HIV infection among women of childbearing age. This was part of
a group of blinded serosurveys, which took advantage of blood
10. Jonathan Hicks, A Wide Impact, From Soup Kitchens to Recycling; Social Services, N.Y. TIMES, Oct. 26, 1994, at B4.
11. Based on vital statistics from the New York State Bureau of Biometrics,
personal communications with New York City hospital labs, and test prices from
Corning Clinical Laboratories, New Jersey. Using the lower estimate for a urine drug/
alcohol screening of $166.85 per screen (range of up to $280). The estimates here are
based on the following costs: $74.20 for a urine alcohol screen, $78.80 for a blood
alcohol screen, $92.65 for a urine drug screen, and $94.50 for a meconium drug screen.
12. Drug screens here refer to a 10-drug panel confirmed with immunoassay
including tests for opiates, PCP, THC, barbiturates, methadone, cocaine and
amphetamines. Alcohol screening requires a separate test.
13. Written Communication from the Bureau of Vital Statistics, New York City
Department of Health, February 26, 1997.
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samples collected for other purposes, to conduct population level
surveillance. 14 This was economically and logistically efficient, because the blood had already been collected. Additionally, there
was no need for informed consent because the serosurvey was
anonymous. These discarded blood samples, together with minimal demographic information, were sent to a separate laboratory
for HIV testing. Specific protections were devised to prevent inadvertent linkage of test results to identifiable individuals.15 As a result, these serosurveillance data cannot provide information about
a particular individual's infection status.
Many sectors of the public did not understand anonymous population surveillance and equated the surveys with withholding
knowledge from individuals. Debate centered on whether there
was an ethical obligation to inform individuals, their partners, or
healthcare providers of infected status. In fact, both confidential
and anonymous testing and counseling were available to individuals while anonymous seroprevalence studies provided critical epidemiologic data and guiding the allocation of resources for
prevention and treatment.
The newborn heelstick survey particularly disturbed some opponents of the anonymous surveys. 6 These opponents argued as if a
dichotomy existed between maternal and infant interests, claiming
that the interests of innocent babies were being sacrificed to selfish
maternal privacy concerns. Congressional bills were introduced to
unblind the National Survey of Childbearing Women. 7 The CDC
then announced the suspension of the survey.18 New York, however, continued to operate the New York State Blinded Survey of
Childbearing Women with its own funds. In 1996, the New York
State legislature passed a law mandating that the results of the
newborn heelstick survey be unblinded.19 The law required an
14. See CENTERS FOR DISEASE CONTROL AND PREVENTION, National HIV Serosurveillance Summary: Results Through 1992 1-5 (1994).
15. George M. Pappaioanou, Jr. et al., HIV Seroprevalence Surveys of Childbearing Women--Objectives, Methods, and Uses of the Data. 105 PUB. HEALTH REP. 147,
147-52 (1990).
16. See Nettie Mayersohn, Letter to the Editor, Don't Abandon Infected Babies,
WALL ST. J., Apr. 24, 1996, at A15; K. Krasinski et al., Failureof Voluntary Testing for
HIV to Identify Infected Partutient Women in a High Risk Population,318 NEW ENG.
J. MED. 185, 185-89 (1988).
17. H.R. 1289, 104th Cong., 1st Sess. (1995).
18. N. Touchette, CDC and Congress at Odds Over Mandatory HIV Testing, 1
NATURE MED. 723, 723-24 (1995).
19. NEW YORK COMP. CODES R. & REGS. tit. 10 § 69 (1997).
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amendment to the State's Confidentiality Law exempting newborn
HIV testing from the informed consent requirements.2 °
Many argue against unblinding the newborn heelstick serosurvey
in terms of maternal autonomy, gender discrimination, bodily integrity, and the right to privacy in medical information. 21 Conversely, advocates of unblinding emphasize the independence of
the newborn and the infant's right to medical care. 22 An assessment of public health efficacy adds another dimension. Such an
assessment reveals a mismatch between the goals and interventions. The goals of the New York State law are unclear, the intervention will be difficult to implement and unrelated to the goal of
preventing vertical transmission. Moreover, we are likely to lose
an important public health tool.
Retroactive unblinding without advanced notification or opportunity to consent violates the ethical premises under which the survey was initiated, and more specifically violates study protocols
granted at the beginning of the project.23 In fact, New York State
had to amend its confidentiality in HIV testing statute to exempt
pregnant women from the universal protections. Recent developments, however, cast doubt on the relevance and efficacy of so doing. The findings of AIDS Clinical Trial Group protocol 076 make
clear that for the purpose of preventing vertical transmission, the
most useful time for maternal identification and treatment is prior
to delivery.24 This finding also underscores the need to inform and
obtain consent from affected women, as they will have to comply
with an onerous medical regime if they elect to take zidovudine
[ZDV].25
20. Id.
21. See Howard Minkoff & Anne Willoughby, PediatricHIV Disease, Zidovudine
in Pregnancy, and Unblinding Heelstick Surveys: Reframing the Debate on Prenatal
HIV Testing, 274 JAMA, 1165, 1167-68 (Oct. 11, 1995); Ana 0. Dumois, The Case
Against Mandatory Newborn Screening for HIV Antibodies, 20 J. OF COMMUNITY
HEALTH 143, 143-159 (Apr. 1, 1995); Fleischman, Mandatory Newborn Screening for
HIV: The Wrong Answer to the Wrong Question, 4 THE AIDS READER 172, 172-174
(1995).
22. Arthur J. Ammann, Unrestricted Routine PrenatalHIV Testing: The Standard
of Care, 50 J. OF THE AM. MED. WOMEN'S ASS'N 83, 83-84 (1995).
23. See Touchette, supra note 18, at 723-24.
24. Edward M. Connor & Rhoda S. Sperling, PediatricAIDS Clinical Trials Group
Protocol 076 Study Group. Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type I with Zidovudine Treatment, 331 NEw ENG. J. MED. 1173,
1173-80 (1994).
25. Ronald Bayer, Ethical Challenges Posed by Zidovudine Treatment to Reduce
Vertical Transmission of HIV, 31 NEW ENG. J. MED. 1223, 1223-25 (1994).
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The unblinding of the newborn serosurvey transpired against the
backdrop of stable HIV prevalence among women delivering, and
a 27% decrease in vertical transmission rates since 1988.26 Furthermore, voluntary testing by pregnant women in New York had risen
significantly from 48% in 1993 to approximately 97% in 1996.27
Data from the author's 1993 survey indicated that only threefourths of publicly funded prenatal care clinics and half of such
gynecologic facilities provided both HIV counseling and testing.28
These respective proportions did not change by 1995.29 Yet both
public health and ethical principles specify that voluntary measures
should be widely available before mandatory ones are instituted.
Outreach and education regarding HIV were even less likely to be
offered at these obstetric and gynecology sites. Implementation of
the new policy is both difficult and expensive. Counseling newly
delivered women places an additional burden on obstetric services,
which already struggle to condense care into forty-eight hours.
Since test results will become available after women go home,
funds and personnel are needed to trace and notify mothers. In
some New York City hospitals as many as two-thirds of HIV-positive women could not be found to receive their results.3 °
This retroactive identification of infected mothers without consent is likely to adversely affect the public trust, and to undermine
the credibility of both public health measures and professionals.
We have failed to learn from earlier experiences with newborn
metabolic screening. For example, Baltimore's Jewish community
was successfully, voluntarily engaged in Tay-Sachs screening, in
contrast to the manner in which newborn sickle cell testing was
implemented.3' In the latter case, insensitivity and coercion led to
32
long term distrust.
26. CENTERS FOR DISEASE CONTROL AND PREVENTION, AIDS among ChildrenUnited States, 276 JAMA 1791, 1791-92 (1996).
27. NEW YORK STATE DEPARTMENT OF HEALTH, AIDS IN NEW YORK STATE
THROUGH 1994 (1995); K. Pass, HIV Testing of Newborns in New York State
(Presented at the Conference of the American Public Health Association, New York,
November 1996).
28. Wendy Chavkin et al., Integrated Reproductive Health Services, 87 AM. J. PUB.
HEALTH 691, 691-92 (1997).
29. Id.
30. Deborah Sontag, HIV Testing for Newborns Debated Anew, N.Y. Times, Feb.
10, 1997, at Al, B6.
31. R.R. FADEN ET AL., AIDS, WOMEN AND THE NEXT GENERATION: TOWARDS
A MORALLY ACCEPTABLE PUBLIC POLICY FOR
AND NEWBORNS

32. Id., n.30.

(1991).
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What does all this mean in the era of welfare reform and managed care?
There are a host of operational and policy questions that have
not yet been analyzed. Do child protective, drug treatment, Temporary Assistance for Needy Families ("TANF") and Medicaid
managed care authorities synchronize plans, especially on an individual case basis? If not, what happens to a woman mandated to
drug treatment if the Medicaid managed care provider will not
cover it? Will women receiving TANF be sanctioned and lose benefits if they have positive toxicology tests at delivery?
Conclusion
We are thus confronted with decreased funding for services, increased sanctions and many policy and logistical conundra. The
symbolic function of depicting the mother in need as a vector of
harm to her children is to obscure the dwindling resources available to her. The rhetoric of rage and blame towards "deviant"
mothers has escalated to embrace poor mothers in general. The
focus on her diverts our attention from the end-of-the-New-Deal
concept of governmental obligation to the citizenry. In an expedient effort to cushion the harshness of these cuts, many will limit
their arguments to the plight of children. We can remind them that
babies need their parents, and we can help infants most by supporting their mothers.
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